These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 8137208)

  • 21. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
    Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II evaluation of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) in advanced, measurable breast carcinoma.
    Langer CJ; Catalano R; Weiner LM; Scher R; Bagchi P; Saren B; Comis RL
    Cancer Invest; 1995; 13(2):150-9. PubMed ID: 7874568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
    Orlando L; Cardillo A; Ghisini R; Rocca A; Balduzzi A; Torrisi R; Peruzzotti G; Goldhirsch A; Pietri E; Colleoni M
    BMC Cancer; 2006 Sep; 6():225. PubMed ID: 16978400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes.
    de Graaf H; Willemse PH; de Vries EG; Sleijfer DT; Mulder PO; van der Graaf WT; Smit Sibinga CT; van der Ploeg E; Dolsma WV; Mulder NH
    Eur J Cancer; 1994; 30A(2):150-3. PubMed ID: 8155387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
    Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
    Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
    Aboud A; Buzdar AU; Yap HY; Hortobagyi GN; Blumenschein GR
    J Surg Oncol; 1984 Jul; 26(3):205-7. PubMed ID: 6610802
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tandem autotransplantation for the treatment of metastatic breast cancer.
    Broun ER; Sridhara R; Sledge GW; Loesch D; Kneebone PH; Hanna M; Hromas R; Cornetta K; Einhorn LH
    J Clin Oncol; 1995 Aug; 13(8):2050-5. PubMed ID: 7636548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
    Yen CC; Tung SL; Hsieh RK; Chiou TJ; Liu JH; Wang WS; Chen PM
    Jpn J Clin Oncol; 1997 Oct; 27(5):316-20. PubMed ID: 9390208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
    Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
    Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
    Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
    Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL
    Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.